On Monday, Linn Energy LLC (NASDAQ:LINE)’s shares declined -2.64% to $12.89.
Linn Energy LLC (LINE) declared monthly distributions and dividends, respectively.
LINN Energy, LLC declared a monthly cash distribution of $0.1042 per unit, or $1.25 per unit on an annualized basis, for all of its outstanding units. The distribution will be payable May 14, 2015, to unitholders of record as of the close of business on May 11, 2015.
Linn Energy, LLC, an independent oil and natural gas company, acquires and develops oil and natural gas properties in the Unites States. Its properties are located in the Rockies, the Hugoton Basin, California, east Texas and north Louisiana, the Mid-Continent, the Permian Basin, Michigan/Illinois, and south Texas.
Cytori Therapeutics Inc (NASDAQ:CYTX)’s shares dropped -2.67% to $0.711.
Cytori Therapeutics Inc (CYTX) declared its first quarter financial results and offered updates on its corporate activity and clinical development.
Selected Q1 Highlights:
Cytori received FDA IDE full approval for Pivotal Phase III trial, STAR TRIAL, to evaluate ECCS-50 in treating hand dysfunction associated with scleroderma – Jan’ 2015
FDA approved an enhance in number of STAR trial sites from 12 to 20 – Feb’ 2015
Enrollment began for ACT-OA, a 90 patient, US Phase II trial, to study ECCO-50 in treating osteoarthritis of the knee - Feb’ 2015
Cytori and Lorem Vascular were granted regulatory clearance for Cytori Celution® System by the State Food and Drug Administration of the People’s Republic of China – Apr’ 2015
Cytori received initial purchase order of Celution devices and 1,100 consumable sets from Lorem Vascular, our Chinese Licensee – Apr’ 2015
Cytori was granted orphan drug status for treatment of scleroderma in European Union – Apr’ 2015
Cytori Therapeutics, Inc., a biotechnology company, develops cell therapeutics for specific diseases and medical conditions. The company primarily provides Cytori Cell Therapy compriseing of a heterogeneous population of specialized cells, counting stem cells for the treatment of patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence, and thermal burns combined with radiation injury.
At the end of Monday’s trade, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)‘s shares dipped -2.61% to $124.08.
Vertex Pharmaceuticals Incorporated (VRTX) stated merged financial results for the quarter ended March 31, 2015. Vertex also reiterated its financial guidance for total 2015 KALYDECO revenues and non-GAAP operating expenses.
First Quarter 2015 Non-GAAP Financial Results
The non-GAAP financial results for the first quarter 2015 and first quarter 2014 exclude stock-based compensation expense, costs related to the relocation of the company’s corporate headquarters, hepatitis C-related revenues and costs and other adjustments.
Total Non-GAAP Revenues: Total non-GAAP revenues for the first quarter of 2015 were $135.4 million, counting $130.2 million in net product revenues from KALYDECO and $5.3 million from royalty revenues.
Net Product Revenues from KALYDECO: Vertex’s first quarter 2015 net product revenues from KALYDECO were $130.2 million contrast to $99.5 million for the first quarter of 2014. The raised KALYDECO net product revenues, contrast to the first quarter of 2014, resulted primarily from additional people being treated with KALYDECO in both U.S. and ex-U.S. markets.
Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases in specialty markets.
VimpelCom Ltd (ADR) (NASDAQ:VIP), ended its Monday’s trading session with -2.59% loss, and closed at $5.27.
VimpelCom Ltd (ADR) (VIP) showed its support for local entrepreneurs via its partnership with StartupAmsterdam, a public-private initiative focused on developing an ecosystem to make Amsterdam one of the top three startup locations in Europe. The two parties hosted one of the TNW (The New Web) LaunchPad Meetups, an initiative that connects startups with the corporate world.
This flagship event, hosted at VimpelCom’s Amsterdam HQ, saw senior business leaders and 30 entrepreneurs talk about areas for partnership on future mobile technologies and the business models that will take the digital world forward.
VimpelCom Ltd. provides telecommunications services in Italy, Russia, Ukraine, Kazakhstan, Uzbekistan, Tajikistan, Armenia, Georgia, Kyrgyzstan, Laos, Algeria, Bangladesh, and Pakistan. It offers voice and data services through a range of traditional and broadband mobile and fixed line technologies.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
